Pomdoctor Ltd. (POM) intrinsic value & 10-year financials
Pomdoctor Ltd. (POM) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 4 fiscal years revenue grew 14.5% a year to $399.9M, with an average return on invested capital of 4.2%.
- Graham intrinsic value
- —
- Revenue (FY2025)
- $399.9M
- Revenue growth (4-yr CAGR)
- 14.5%
- ROIC (10-yr avg)
- 4.2%
- Free cash flow (FY2025)
- -$149.5M
POM 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $399.9M | -$130.9M | -$21.96 | -$149.5M | -29.7% | 9.0% |
| FY2024 | $342.6M | -$37.4M | -$22.72 | -$16.2M | -7.5% | 1.7% |
| FY2023 | $304.9M | -$36.9M | -$23.04 | -$45.9M | -7.3% | 1.8% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
POMDOCTOR Ltd revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
POMDOCTOR Ltd has historically struggled to out-earn its cost of capital, averaging just 5.3% ROIC.
POMDOCTOR Ltd capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, POMDOCTOR Ltd is modeled at 14.5% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-711.99 per share.